FK506 and deoxyspergualin: experimental studies and clinical applications
- 30 September 1994
- journal article
- review article
- Published by Elsevier in Transplant Immunology
- Vol. 2 (3), 190-198
- https://doi.org/10.1016/0966-3274(94)90060-4
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- THE EFFECTS OF FK506 AND CYCLOSPORINE ON THE EXOCRINE FUNCTION OF THE RAT PANCREASTransplantation, 1992
- THE SALUTARY EFFECT OF FK506 IN ISCHEMIA-REPERFUSION INJURY OF THE CANINE LIVERTransplantation, 1992
- FK506-INDUCED IMPAIRMENT OF GLUCOSE METABOLISM IN THE PRIMATE—STUDIES IN PANCREATIC TRANSPLANT RECIPIENTS AND IN NONTRANSPLANTED ANIMALSTransplantation, 1992
- In vivo31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK 506Heart and Vessels, 1990
- EVIDENCE THAT DEOXYSPERGUALIN PREVENTS SENSITIZATION AND FIRST-SET CARDIAC XENOGRAFT REJECTION IN RATS BY SUPPRESSION OF ANTIBODY FORMATIONTransplantation, 1990
- Effects of a novel immunosuppressive agent, FK506, on human B cell activationClinical and Experimental Immunology, 1990
- PROLONGATION OF CARDIAC ALLOGRAFT SURVIVAL IN RATS BY RECIPIENT PRETREATMENT WITH DONOR SPLEEN CELLS AND 15-DEOXYSPERGUALINTransplantation, 1989
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989
- PROLONGATION OF SKIN ALLOGRAFT SURVIVAL IN RATS BY A NOVEL IMMUNOSUPPRESSIVE AGENT, FK 506Transplantation, 1988
- Prolongation of graft survival in allogeneic islet transplantation by (−) 15-deoxyspergualin in the ratDiabetologia, 1987